Zealand Pharma — Maj 2022
-
Zealand Pharma banker op på børsen efter frasalg af insulinpumpe
Zealand Pharma henter lidt tilbage af det tabte på aktiemarkedet, efter selskabet har haft sucess med at sikre sig et frasalg af insulinpumpen V-Go.
Zealand Pharma banker op på børsen efter frasalg af insulinpumpe
Zealand Pharma henter lidt tilbage af det tabte på aktiemarkedet, efter selskabet har haft sucess med at sikre sig et frasalg af insulinpumpen V-Go.
(medwatch.dk)
-
Flere spørgsmål til Q&A er meget velkommen.
-
clinicaltrials.gov - May 18, 2022 Drug: Dasiglucagon Phase 3: "A Research Study to Investigate the Safety and Effect of Dasiglucagon as a Hypoglycemia Rescue Therapy and How it Works in the Body of Children Under 6 Years of Age With Type 1 Diabetes" (Not yet recruiting).
-
@exitnu - nogen fornemmelse hvorfor det fine momentum idag?
-
har set dit svar under bava, tak
-
nu går den helt balalejka
-
du er en stjerne tak
-
Zealand Pharma Announces Positive Results from Phase 3 Trial of Dasiglucagon in Pediatric Patients with Congenital Hyperinsulinism (CHI)
Company announcement – No. 22 / 2022 Zealand Pharma Announces Positive Results from Phase 3 Trial of Dasiglucagon in Pediatric Patients with Congenital...
GlobeNewswire News Room (www.globenewswire.com)
-
Dasiglucagon treatment was assessed as well-tolerated in this study and 11 out of 12 patients are continuing into the long-term safety extension study.
These data, together with data from a previously reported Phase 3 study in older children with CHI, are expected to form the basis of a new drug application (NDA) for dasiglucagon treatment in the management of CHI, with the U.S. Food and Drug Administration. Submission is anticipated by end of 2022. -
2 og 4 mest shortede aktier i DKK op 23% og 6% i rødt marked.
-
og os:)
-
"Based on the trial’s results, Zealand Pharma will engage with the U.S. Food and Drug Administration to discuss the submission of an NDA for marketing approval. Dasiglucagon has the potential to become the first medicine developed specifically for this debilitating, ultra-rare disease in over three decades."
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind